Literature DB >> 9020859

Comparative studies of rat recombinant purple acid phosphatase and bone tartrate-resistant acid phosphatase.

B Ek-Rylander1, T Barkhem, J Ljusberg, L Ohman, K K Andersson, G Andersson.   

Abstract

The tartrate-resistant acid phosphatase (TRAP) of rat osteoclasts has been shown to exhibit high (85-94%) identity at the amino acid sequence level with the purple acid phosphatase (PAP) from bovine spleen and with pig uteroferrin. These iron-containing purple enzymes contain a binuclear iron centre, with a tyrosinate-to-Fe(III) charge-transfer transition responsible for the purple colour. In the present study, production of rat osteoclast TRAP could be achieved at a level of 4.3 mg/litre of medium using a baculovirus expression system. The enzyme was purified to apparent homogeneity using a combination of cation-exchange, hydrophobic-interaction, lectin-affinity and gel-permeation chromatography steps. The protein as isolated had a purple colour, a specific activity of 428 units/mg of protein and consisted of the single-chain form of molecular mass 34 kDa, with only trace amounts of proteolytically derived subunits. The recombinant enzyme had the ability to dephosphorylate bone matrix phosphoproteins, as previously shown for bone TRAP. Light absorption spectroscopy of the isolated purple enzyme showed a lambda max at 544 nm, which upon reduction with ascorbic acid changed to 515 nm, concomitant with the transition to a pink colour. EPR spectroscopic analysis of the reduced enzyme at 3.6 K revealed a typical mu-hydr(oxo)-bridged mixed-valent Fe(II)Fe(III) signal with g-values at 1.96, 1.74 and 1.60, proving that recombinant rat TRAP belongs to the family of PAPs. To validate the use of recombinant PAP in substituting for the rat bone counterpart in functional studies, various comparative studies were carried out. The enzyme isolated from bone exhibited a lower K(m) for p-nitrophenyl phosphate and was slightly more sensitive to PAP inhibitors such as molybdate, tungstate, arsenate and phosphate. In contrast with the recombinant enzyme, TRAP from bone was isolated predominantly as the proteolytically cleaved, two-subunit, form. Both the recombinant enzyme and rat bone TRAP were shown to be substituted with N-linked oligosaccharides. A slightly higher apparent molecular mass of the monomeric form and N-terminal chain of bone TRAP compared with the recombinant enzyme could not be accounted for by differential N-glycosylation. Despite differences in specific post-translational modifications, the recombinant PAP should be useful in future studies on the properties and regulation of the mammalian PAP enzyme.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9020859      PMCID: PMC1218069          DOI: 10.1042/bj3210305

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Histochemical investigations on the localization of the purple acid phosphatase in the bovine spleen.

Authors:  J Schindelmeiser; D Münstermann; H Witzel
Journal:  Histochemistry       Date:  1987

2.  Physical characterization of two-iron uteroferrin. Evidence for a spin-coupled binuclear iron cluster.

Authors:  B C Antanaitis; P Aisen; H R Lilienthal
Journal:  J Biol Chem       Date:  1983-03-10       Impact factor: 5.157

3.  Iron-containing acid phosphatases: interaction of phosphate with the enzyme from pig allantoic fluid.

Authors:  D T Keough; J L Beck; J de Jersey; B Zerner
Journal:  Biochem Biophys Res Commun       Date:  1982-10-29       Impact factor: 3.575

4.  Effects of perturbants on the pink (reduced) active form of uteroferrin. Phosphate-induced anaerobic oxidation.

Authors:  B C Antanaitis; P Aisen
Journal:  J Biol Chem       Date:  1985-01-25       Impact factor: 5.157

5.  The interaction of phosphate with the purple acid phosphatase from beef spleen: evidence that phosphate binding is accompanied by oxidation of the iron chromophore.

Authors:  S Burman; J C Davis; M J Weber; B A Averill
Journal:  Biochem Biophys Res Commun       Date:  1986-04-29       Impact factor: 3.575

6.  The interaction of phosphate with uteroferrin. Characterization of a reduced uteroferrin-phosphate complex.

Authors:  J W Pyrz; J T Sage; P G Debrunner; L Que
Journal:  J Biol Chem       Date:  1986-08-25       Impact factor: 5.157

7.  Isolation and characterization of a high molecular weight stable pink form of uteroferrin from uterine secretions and allantoic fluid of pigs.

Authors:  G A Baumbach; C M Ketcham; D E Richardson; F W Bazer; R M Roberts
Journal:  J Biol Chem       Date:  1986-09-25       Impact factor: 5.157

8.  Spectroscopic and kinetics studies of a high-salt-stabilized form of the purple acid phosphatase from bovine spleen.

Authors:  J B Vincent; M W Crowder; B A Averill
Journal:  Biochemistry       Date:  1991-03-26       Impact factor: 3.162

9.  Purification and characterization of a vanadate-sensitive nucleotide tri- and diphosphatase with acid pH optimum from rat bone.

Authors:  G Andersson; B Ek-Rylander; L Hammarström
Journal:  Arch Biochem Biophys       Date:  1984-02-01       Impact factor: 4.013

10.  Detection of a g' = 1.74 EPR signal in bovine spleen purple acid phosphatase.

Authors:  B C Antanaitis; P Aisen
Journal:  J Biol Chem       Date:  1982-05-25       Impact factor: 5.157

View more
  16 in total

1.  Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases.

Authors:  J Ljusberg; B Ek-Rylander; G Andersson
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Polarization and secretion of cathepsin K precede tartrate-resistant acid phosphatase secretion to the ruffled border area during the activation of matrix-resorbing clasts.

Authors:  Karin Hollberg; Joakim Nordahl; Kjell Hultenby; Silwa Mengarelli-Widholm; Göran Andersson; Finn P Reinholt
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Direct observation of multiple protonation states in recombinant human purple acid phosphatase.

Authors:  Enrico G Funhoff; Thyra E de Jongh; Bruce A Averill
Journal:  J Biol Inorg Chem       Date:  2005-09-23       Impact factor: 3.358

4.  Simvastatin-doped pre-mixed calcium phosphate cement inhibits osteoclast differentiation and resorption.

Authors:  M Montazerolghaem; A Rasmusson; H Melhus; H Engqvist; M Karlsson Ott
Journal:  J Mater Sci Mater Med       Date:  2016-03-11       Impact factor: 3.896

5.  Differential expression of tartrate-resistant acid phosphatase isoforms 5a and 5b by tumor and stromal cells in human metastatic bone disease.

Authors:  Serhan Zenger; Wentao He; Barbro Ek-Rylander; Daphne Vassiliou; Rickard Wedin; Henrik Bauer; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2010-10-22       Impact factor: 5.150

6.  Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism.

Authors:  Kirsten M Robertson Remen; Petra Henning; Ulf H Lerner; Jan-Åke Gustafsson; Göran Andersson
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

7.  Induction and cellular expression of tartrate resistant acid phosphatase during dextran sodium sulphate induced colitis in rats.

Authors:  Pernilla Lång; Stefan Lange; Dick Delbro; Göran Andersson
Journal:  Histochem Cell Biol       Date:  2009-10-11       Impact factor: 4.304

8.  Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts.

Authors:  Y Wittrant; Y Gorin; S Mohan; B Wagner; S L Abboud-Werner
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

9.  High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis.

Authors:  Y Wittrant; Y Gorin; K Woodruff; D Horn; H E Abboud; S Mohan; S L Abboud-Werner
Journal:  Bone       Date:  2008-02-29       Impact factor: 4.398

10.  Monomeric tartrate resistant acid phosphatase induces insulin sensitive obesity.

Authors:  Pernilla Lång; Vanessa van Harmelen; Mikael Rydén; Maria Kaaman; Paolo Parini; Claes Carneheim; A Ian Cassady; David A Hume; Göran Andersson; Peter Arner
Journal:  PLoS One       Date:  2008-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.